This company develops a portable inflammometer that analyzes lung function and exhaled gases to monitor lung health. The device provides healthcare professionals with an easy and precise alternative to traditional monitoring tools for managing patients' respiratory conditions.
Funding
Funding not disclosed
Founders
Product
Problem
Current methods for monitoring lung health often rely on bulky, expensive equipment and can be inconvenient for patients, especially those with asthma or those in developing countries. Traditional lung function tests may not be easily accessible or affordable, hindering proactive management of respiratory conditions.
Solution
SPIROMANN is developing the IPPI (Intelligent Personal Portable Inflammometer), a handheld device designed for convenient and affordable lung health monitoring. The IPPI analyzes lung function and exhaled gases, specifically fractional exhaled Nitric Oxide (FeNO), to provide insights into lung health. This allows users to monitor their respiratory condition from anywhere, facilitating timely intervention and improved quality of life. The device aims to offer a faster, cheaper, and more user-friendly alternative to existing lung monitoring solutions.
Target Audience
The primary target audience includes individuals with asthma, healthcare professionals seeking accessible monitoring tools, and individuals in developing countries with limited access to traditional lung health management resources.
Features
- Handheld, portable design for on-the-go lung health monitoring
- Measures and analyzes fractional exhaled Nitric Oxide (FeNO) levels
- Provides real-time physiological response monitoring
- Aims to be a more affordable alternative to existing devices
- Designed for ease of use by patients at home or in remote locations